Prices are closing data as of 2026-11-09, not real-time quotes. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for NEUROCRINE BIOSCIENCES INC?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Key Multi-Year Facts
- Revenue moved from $15.0M in FY2016 to $2.86B in FY2025 (9-year CAGR +79.2%).
- Net income was negative in FY2016, FY2017.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (USD B) | 1.13 | 1.49 | 1.89 | 2.36 | 2.86 |
| YoY | 8.4% | 31.3% | 26.8% | 24.8% | 21.4% |
| Net Income (USD B) | 0.09 | 0.15 | 0.25 | 0.34 | 0.48 |
| YoY | -78.0% | 72.4% | 61.6% | 36.7% | 40.2% |
| Operating Cash Flow (USD B) | 0.26 | 0.34 | 0.39 | 0.60 | 0.78 |
| ROE | 7.2% | 10.0% | 12.7% | 14.2% | 16.4% |
| Gross Margin | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% |
| Net Margin | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| Debt-to-Assets | 33.7% | 27.9% | 31.4% | 30.4% | 29.8% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD B) | 0.01 | 0.16 | 0.45 | 0.79 | 1.05 | 1.13 | 1.49 | 1.89 | 2.36 | 2.86 |
| YoY | — | 977.5% | 179.2% | 74.7% | 32.7% | 8.4% | 31.3% | 26.8% | 24.8% | 21.4% |
| Net Income (USD B) | -0.14 | -0.14 | 0.02 | 0.04 | 0.41 | 0.09 | 0.15 | 0.25 | 0.34 | 0.48 |
| YoY | — | — | — | 75.4% | 1000.8% | -78.0% | 72.4% | 61.6% | 36.7% | 40.2% |
| Operating Cash Flow (USD B) | -0.11 | -0.09 | 0.10 | 0.15 | 0.23 | 0.26 | 0.34 | 0.39 | 0.60 | 0.78 |
| ROE | -44.8% | -41.5% | 4.9% | 6.6% | 46.2% | 7.2% | 10.0% | 12.7% | 14.2% | 16.4% |
| Gross Margin | 100.0% | 99.2% | 98.9% | — | 99.0% | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% |
| Net Margin | -940.6% | -88.2% | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| Debt-to-Assets | 13.8% | 54.5% | 51.6% | 51.2% | 35.1% | 33.7% | 27.9% | 31.4% | 30.4% | 29.8% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: SEC XBRL filings, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-10
Rules-based screening using SEC XBRL financial data and 8-K/NT material event filings (no AI opinions).
Items Flagged for Review
- Watch
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
More U.S. data: 500 largest U.S. companies · U.S. high dividend stocks · Is the stock market open today?
Compiled mechanically from public filings and market quotes (data as of 2026-11-10). For informational purposes only, not investment advice.